D-0465-2023 Class III Terminated

Recalled by AVEVA Drug Delivery Systems, Inc. — Miramar, FL

FDA drug recall D-0465-2023 was initiated by AVEVA Drug Delivery Systems, Inc. on Feb 15, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 11,520 cartons.

Recall details

Product Type
Drugs
Report Date
Mar 22, 2023
Initiation Date
Feb 15, 2023
Termination Date
Apr 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,520 cartons

Product description

Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of 4 disposal units, Rx Only, Manufactured by: Aveva Drug Delivery Systems Inc. Miramar, FL. 33025, Manufactured for: Apotex Corp Weston, FL. 33326, NDC 60505-7077-05

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.

Distribution pattern

Nationwide

Code information

Lot#: 51835 Exp: 06/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0465-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0465-2023. Report a data issue: hello@regdatalab.com.